Companies ORAMED PHARMACEUTICALS INC.
ORAMED PHARMACEUTICALS (ORMP): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me ORAMED PHARMACEUTICALS INC.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,659,222FY2023
- $2,097,689FY2024
- $4,774,460FY2025
CEO total pay was $4,774,460 in fiscal 2025, up from $2,097,689 in fiscal 2024.
FY2025: salary $619,529 · bonus $379,935 · stock awards $3,709,269 · option awards $0
Order ORMP
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nadav Kidron | $619,529 | $379,935 | $3,709,269 | $0 | $0 | $0 | $65,927 | $4,774,460 |
| President, Chief Executive Officer and Chairman | ||||||||
| Miriam Kidron | 439,902 | 271,994 | 1,406,033 | 0 | 0 | 0 | 48,455 | 2,166,384 |
| Chief Scientific Officer and director (5) | ||||||||
| Joshua Hexter | 285,432 | 218,148 | 1,299,065 | 0 | 0 | 0 | 79,753 | 1,882,398 |
| Chief Operating and Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nadav Kidron | $4,774,460 | $2,097,689 | $1,659,222 | ↑ +2,676,771 |
| Miriam Kidron | 2,166,384 | 1,534,547 | 1,109,431 | ↑ +631,837 |
| Joshua Hexter | 1,882,398 | 1,031,450 | 728,440 | ↑ +850,948 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is not explicitly detailed in the provided text, but the Compensation Committee is responsible for reviewing, negotiating, and approving salaries and incentive compensation, and administering equity-based plans. Bonuses are granted at the discretion of the Compensation Committee.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joshua Hexter | Option | 9,000 | 13.89 | — |
| Kidron | Option | 18,000 | 13.89 | — |
| Kidron | Option | 26,750 | 13.89 | — |
| Joshua Hexter | Option | 100,000 | 3.69 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Daniel AghionIndependent · Audit · Investment · Compensation | $42,790 | $185,810 | $0 | — | $0 | $228,600 |
| Yehuda ReznickIndependent · Audit · Investment · Compensation · Partial-year service | 42,790 | 185,808 | 0 | — | 0 | 228,598 |
| Dr. Arie MayerIndependent · Audit · Nominating and Corporate Governance | 40,000 | 178,961 | 0 | — | 0 | 218,961 |
| Benjamin ShapiroIndependent | 30,000 | 169,973 | 0 | — | 0 | 199,973 |
| Leonard SankIndependent · Compensation · Nominating and Corporate Governance · Not standing for re-election · Departed during FY | 38,500 | 78,497 | 0 | — | 0 | 116,997 |
Board fee structure and ownership guideline
| Annual cash retainer | $30,000 |
|---|---|
| Annual equity retainer | $10,000 |
| Per board meeting fee | $500 |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $194,080 |
| Equity awards (grant-date value) | $799,049 |
| All other compensation | $0 |
| Total cost of the board | $993,129 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ORAMED PHARMACEUTICALS as a peer
Companies that benchmark against ORMP
No companies currently name ORMP as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | ORAMED PHARMACEUTICALS INC. | 2025 | Nadav Kidron | $619,529 | $3,709,269 | $0 | $0 | $4,774,460 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-08-01 | 9,171,779 | 1,016,334 | 74,388 | 90.02% | Passed |
| 2022 | 2022-06-30 | 10,073,933 | 1,100,188 | 106,011 | 90.15% | Passed |
| 2020 | 2020-08-03 | 7,275,546 | 299,671 | 188,778 | 93.71% | Passed |
| 2018 | 2018-08-28 | 3,661,606 | 889,122 | 31,149 | 80.46% | Passed |
| 2016 | 2016-08-30 | 2,970,134 | 117,293 | 1,228,900 | 96.2% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-08-01 | 90.02%a |
| 2022 | 2022-06-30 | 90.15%b |
| 2020 | 2020-08-03 | 93.71%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “With respect to all matters to be voted on, abstentions will have the same effect as a vote against such matters.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nadav Kidron. DEF 14A, filed 2026-08-03. Section “Executive Compensation”. As printed: 4,774,460. View filing ↗
- Section 01, Miriam Kidron. DEF 14A, filed 2026-08-03. Section “Executive Compensation”. As printed: 2,166,384. View filing ↗
- Section 01, Joshua Hexter. DEF 14A, filed 2026-08-03. Section “Executive Compensation”. As printed: 1,882,398. View filing ↗
- Section 08, Dr. Daniel Aghion. DEF 14A, filed 2026-08-03. Section “Director Compensation”. As printed: 228,600. View filing ↗
- Section 08, Yehuda Reznick. DEF 14A, filed 2026-08-03. Section “Director Compensation”. As printed: 228,598. View filing ↗
- Section 08, Dr. Arie Mayer. DEF 14A, filed 2026-08-03. Section “Director Compensation”. As printed: 218,961. View filing ↗
- Section 08, Benjamin Shapiro. DEF 14A, filed 2026-08-03. Section “Director Compensation”. As printed: 199,973. View filing ↗
- Section 08, Leonard Sank. DEF 14A, filed 2026-08-03. Section “Director Compensation”. As printed: 116,997. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-08-02. Item 5.07 · say-on-pay result. As reported: 90.02% (votes for as printed: 9,171,779). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-30. Item 5.07 · say-on-pay result. As reported: 90.15% (votes for as printed: 10,073,933). View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-08-04. Item 5.07 · say-on-pay result. As reported: 93.71% (votes for as printed: 7,275,546). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 194,080 + equity 799,049 + all other 0 = 993,129, summed across the director compensation table rows.
- ORAMED PHARMACEUTICALS INC. (subject), Section 10b CEO total. DEF 14A, filed 2026-08-03. CEO total compensation as printed in ORAMED PHARMACEUTICALS INC.'s own proxy. As printed: 4,774,460. View filing ↗